The prognosis for<unk>  is superior in children and increased age is a negative prognostic indicator. The overall cure rate for sporadic<unk>  in developed countries is about 90%. In adults,<unk>  is uncommon and has poor outcomes. Unsatisfactory initial response to the treatment of<unk>  with cyclophosphamide, vincristine, and prednisolone indicates a negative prognosis. Furthermore, failed initial treatment and return of<unk>  after a 6-month stint of time serve as a poor prognostic indicator. The adequate utilization of therapeutic drugs during initial treatment limits additional treatment options following the return of the disease. Notably, in areas of the world where the initial treatment of<unk>  is inadequate further treatment options may remain for cases when the disease returns. Laboratory studies such as lactate dehydrogenase (LDH), CD4 count, and other cytogenetic studies are also prognostic indicators. Unsatisfactory outcomes have been associated with an LDH that is found to be two times above the upper limit of normal. Specifically, there is a poor prognosis associated with a CD4 count that is decreased in the immunodeficiency-associated variant of<unk> . Genetic mutations extending beyond the previously described MYC translocation may also serve as negative prognostic indicators. Some notable genetic findings that may be associated with poor outcomes include: 13q deletion, 7q gain, ID3 and CCND3 double-hit mutations, and 18q21 CN-LOH mutations. The prognosis for<unk>  can be better determined following staging utilizing imaging modalities such as positron emission tomography and computed tomography scans where tumor burden and invasion of the central nervous system have been found to indicate a poor prognosis.
Burkitt lymphoma
Hodgkin lymphoma
AIDS-related lymphoma
Thymic carcinoma
B-cell lymphoma
Thymoma with immunodeficiency
Diffuse large B-cell lymphoma
Mantle cell lymphoma